Publications by authors named "Gail Roboz"

Claim this Profile
O
Oral azacitidine maintenance therapy for patients with acute myeloid leukaemia and myelodysplasia-related changes: Post hoc analysis of the QUAZAR AML-001 trial.
Maria Teresa Voso, Stéphane de Botton, Michael Pfeilstöcker, Angela Figuera Alvarez, Kefeng Wang, Gail J Roboz

Br J Haematol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
2
2025 Update on MRD in Acute Myeloid Leukemia: A Consensus Document from the ELN-DAVID MRD Working Party.
Jacqueline Cloos, Peter J M Valk, Christian Thiede, Konstanze Döhner, Gail J Roboz

Blood· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1 study of IO-202, an anti-LILRB4 antibody, in chronic myelomonocytic leukemia and acute myeloid leukemia.
Ahmed Aribi, Gabriel N Mannis, Yazan F Madanat, Brian A Jonas, Neil Dunavin, Gail J Roboz

Blood Neoplasia· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Z
Ziftomenib in Relapsed or Refractory -Mutated AML.
Eunice S Wang, Pau Montesinos, James Foran, Harry Erba, Eduardo Rodríguez-Arbolí, Gail J Roboz

J Clin Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Measurable residual disease-guided interventions in patients with acute myeloid leukaemia undergoing allogeneic haematopoietic cell transplantation: best practice recommendations from the European Society for Blood and Marrow Transplantation Practice Harmonisation and Guidelines Committee.
Jaime Sanz, Gesine Bug, Fabio Ciceri, Charles Craddock, Richard Dillon, Gail J Roboz

Lancet Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk stratification of low-dose cytarabine and venetoclax in patients with AML ineligible for intensive chemotherapy.
Andrew H Wei, Panayiotis Panayiotidis, Pau Montesinos, Kamel Laribi, Vladimir Ivanov, Gail J Roboz

Blood Adv· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Standardization of Bone Marrow Reporting for Myelodysplastic Syndromes/Neoplasms on Behalf of the International Consortium for Myelodysplastic Syndromes/Neoplasms.
Savanah D Gisriel, Fnu Aakash, John M Bennett, Robert P Hasserjian, Sanam Loghavi, Gail J Roboz

Arch Pathol Lab Med· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Olutasidenib alone or combined with azacitidine in patients with mutant IDH1 myelodysplastic syndrome.
Jorge E Cortes, Jay Yang, Gail J Roboz, Shira N Dinner, Eunice S Wang

Blood Adv· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single-cell spatial mapping reveals dynamic bone marrow microarchitectural alterations and enhances clinical diagnostics in MDS.
Ryan Nachman, Aleksandra Kopacz, Caitlin Unkenholz, Jian Chai, Arvin Ruiz, Gail J Roboz

bioRxiv· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Wild-type p53 overexpression in -mutated acute myeloid leukemia: potential implications for disease biology and therapy response.
Paul D Barone, Siarhei Dzedzik, Ashley S Kleinman, Christopher R Chin, Cem Meydan, Gail J Roboz

Haematologica· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of oral decitabine/cedazuridine in the chronic myelomonocytic leukaemia subpopulations from phase 2 and 3 studies.
Michael R Savona, Olatoyosi Odenike, Gail J Roboz, Harshad Amin, Amy E DeZern

Br J Haematol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Measurable residual disease (MRD) as a surrogate end point for clinical drug approval in acute myeloid leukemia (AML): Perspectives from the MRD Partnership and Alliance in AML Clinical Treatment Consortium.
Michael Boyiadzis, Andrew H Wei, Bruno Paiva, Sylvie D Freeman, Gertjan Kaspers, Gail J Roboz

Cancer· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term follow-up and combined Phase 2 results of eprenetapopt and azacitidine in patients with mutant MDS/AML.
David A Sallman, Rami S Komrokji, Amy E Dezern, Marie Sebert, Guillermo Garcia-Manero, Gail J Roboz

Hemasphere· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High incidence of multi-joint osteonecrosis in first year following treatment for acute lymphoblastic leukemia.
Alison K Heilbronner, Olivia Blumberg, Alexandra Krez, Donald J McMahon, Douglas N Mintz, Gail J Roboz

Leuk Lymphoma· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A plain language summary of the ASCERTAIN trial: oral decitabine and cedazuridine versus intravenous decitabine for MDS or CMML.
Guillermo Garcia-Manero, James McCloskey, Elizabeth A Griffiths, Karen W L Yee, Amer M Zeidan, Gail J Roboz

Future Oncol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
How I use maintenance therapy in acute myeloid leukemia.
Gail J Roboz, Jonathan Canaani

Blood· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reducing clinical trial eligibility barriers for patients with MDS: an icMDS position statement.
Uma Borate, Kelly Pugh, Allyson Waller, Rina Li Welkie, Ying Huang, Gail J Roboz

Blood· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oral decitabine cedazuridine with and without venetoclax in higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia: a propensity score-matched study.
Alex Bataller, Koji Sasaki, Samuel Urrutia, Guillermo Montalban-Bravo, Alexandre Bazinet, Gail J Roboz

Blood Cancer J· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Deficit accumulation frailty index and treatment tolerability in AML: data from CALGB 11001 and 11002 (Alliance).
Catherine Lai, Minji Lee, Olivia Bobek, Jennifer Le-Rademacher, Sumithra Mandrekar, Gail J Roboz

Blood Adv· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Olutasidenib in combination with azacitidine induces durable complete remissions in patients with relapsed or refractory mIDH1 acute myeloid leukemia: a multicohort open-label phase 1/2 trial.
Jorge E Cortes, Gail J Roboz, Maria R Baer, Brian A Jonas, Gary J Schiller

J Hematol Oncol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Contemporary Approach to the Diagnosis and Classification of Myelodysplastic Neoplasms/Syndromes-Recommendations From the International Consortium for Myelodysplastic Neoplasms/Syndromes (MDS [icMDS]).
Fnu Aakash, Savanah D Gisriel, Amer M Zeidan, John M Bennett, Rafael Bejar, Gail J Roboz

Mod Pathol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Frontline treatment of adults with newly diagnosed B-cell acute lymphoblastic leukaemia.
Ibrahim Aldoss, Gail J Roboz, Renato Bassan, Nicolas Boissel, Daniel J DeAngelo

Lancet Haematol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of clonal hematopoiesis and mosaic chromosomal alterations with solid malignancy incidence and mortality.
Pinkal Desai, Ying Zhou, Justin Grenet, Samuel K Handelman, Cynthia M Crispino, Gail Roboz

Cancer· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Transplant Outcomes in Myelofibrosis: Impact of Donor Type (Cord Blood Grafts Supported by CD34+ selected Cells [Haplo-Cord] Versus Matched Donors).
Nima Ghalehsari, Franco Castillo Tokumori, Zhengming Chen, Marie Liu, Sebastian A Mayer, Gail J Roboz

Transplant Cell Ther· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Data-driven, harmonised classification system for myelodysplastic syndromes: a consensus paper from the International Consortium for Myelodysplastic Syndromes.
Rami S Komrokji, Luca Lanino, Somedeb Ball, Jan P Bewersdorf, Monia Marchetti, Gail J Roboz

Lancet Haematol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis